Scientists Find Body's "Off Switch" for Inflammation

Scientists at University College London have identified the body's natural mechanism for ending inflammation, a discovery that could transform how we treat chronic diseases affecting millions worldwide.

Inflammation helps us heal from injuries and fight infections, but when it doesn't switch off properly, it damages healthy tissue and drives conditions like arthritis, heart disease, and diabetes. Until now, scientists understood how inflammation starts but not how the body knows when to stop.

The research team found that small fat-derived molecules called epoxy-oxylipins act like natural brakes on the immune system. These molecules prevent harmful white blood cells from accumulating and causing the kind of persistent inflammation that leads to chronic disease.

To test their theory in humans, researchers injected 48 volunteers with dead bacteria that triggered temporary inflammation similar to an injury. Half received a drug called GSK2256294 that keeps protective epoxy-oxylipins active in the body, while the other half received a placebo.

The results were striking. Volunteers who received the drug experienced faster pain relief and showed significantly fewer harmful immune cells in their blood and tissue. The treatment worked whether given before inflammation started or after symptoms appeared.

The Bright Side

Most anti-inflammatory drugs work by suppressing the immune system, which can leave people vulnerable to infections. This discovery offers a different path: strengthening the body's own shutdown mechanism rather than fighting against its natural defenses.

The drug used in the study already exists and is safe for human use, meaning it could potentially be repurposed quickly to treat inflammatory flare-ups. Dr. Olivia Bracken, the study's lead author, noted this could be especially important for autoimmune diseases, where current treatment options remain limited.

The research, published in Nature Communications, marks the first time scientists have mapped how these protective molecules work in humans during active inflammation. By understanding the exact pathway, researchers can now design treatments that help the body restore its own immune balance.

Professor Derek Gilroy, who led the study, emphasized that this entirely human-based research has direct relevance to treating chronic inflammatory conditions. The team identified the specific protein pathway that epoxy-oxylipins suppress to prevent harmful immune cell transformation.

With chronic inflammation recognized as a major global health threat, this natural braking system could offer hope to people seeking relief without the side effects of immune suppression.